Retifanlimab Levels and Effects while Breastfeeding
Summary of Use during Lactation
No information is available on the clinical use of retifanlimab during breastfeeding. Because retifanlimab is a large protein molecule with a molecular weight of 148,000 Da, the amount in milk is likely to be very low. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal. Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant.[1] The manufacturer recommends avoiding breastfeeding during therapy and for 4 months after the last dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
References
1.
Krysko KM, Dobson R, Alroughani R, et al. Family planning considerations in people with multiple sclerosis. Lancet Neurol. 2023;22:350–66. [PubMed: 36931808]
Substance Identification
Substance Name
Retifanlimab
CAS Registry Number
2079108-44-2
Drug Class
Breast Feeding
Lactation
Milk, Human
Antibodies, Monoclonal
Antineoplastic Agents
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
